Loading...
01/11 08:24
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The company reported significant revenue growth and improved gross margins, indicating strong financial performance. Despite increased operating expenses leading to a net loss, the guidance remains optimistic with continued investments in growth. The Q&A revealed some uncertainties about future guidance and FDA submissions, but the overall market strategy and expansion plans are positive. The stock price is likely to react positively over the next two weeks, especially given the record revenue growth and optimistic outlook for 2025.
Q4 2024 Revenue $18.5 million, a 41% increase from $13.1 million in Q4 2023, driven by continued commercial expansion and increased adoption of the CeriBell System.
Full-Year 2024 Revenue $65.4 million, representing a 45% growth over 2023, attributed to successful account acquisition and utilization.
Q4 2024 Product Revenue $14.1 million, a 41% increase from $10.0 million in Q4 2023, driven by commercial expansion.
Q4 2024 Subscription Revenue $4.4 million, a 40% increase from $3.1 million in Q4 2023, reflecting growth in active accounts.
Q4 2024 Gross Margin 88%, compared to 85% in Q4 2023, due to improved manufacturing efficiency and volume-based leverage.
Full-Year 2024 Gross Margin 87%, compared to 84% in 2023, reflecting continued efficiency improvements.
Q4 2024 Operating Expenses $29.1 million, a 49% increase compared to $19.5 million in Q4 2023, primarily due to investments in the commercial organization and increased headcount.
Full-Year 2024 Operating Expenses $96.5 million, an increase of 41% compared to $68.2 million in 2023, driven by investments in growth and public company-related costs.
Q4 2024 Net Loss $12.6 million, or a loss of $0.40 per share, compared to a loss of $8.3 million or a loss of $1.53 per share in Q4 2023, reflecting increased operating expenses.
Full-Year 2024 Net Loss $40.5 million, or a loss of $3.39 per share, compared to a loss of $29.5 million or a loss of $5.56 per share in 2023, due to higher operating expenses.
Cash and Cash Equivalents $194.4 million as of December 31, 2024, including net proceeds of approximately $188 million from the October IPO.
Product Revenue Q4 2024: Product revenue for the fourth quarter of 2024 was $14.1 million, representing an increase of 41% from $10.0 million in the fourth quarter of 2023.
New Product Indication: We expect to have Clarity indication expanded to include pediatric patients following our submission of a 510(k) application with FDA in late 2024.
New Algorithm Development: We are also working this year to finalize the development and testing of our neonate Clarity algorithm ahead of the submission of a separate 510(k) application in 2026.
Stroke Detection Algorithm: We have recently accelerated our investment in the development of a stroke detection algorithm, having collected data on over 200 patients.
Active Accounts: Our active account set at 529 accounts as of December 31, an increase of 25 during the first quarter.
Market Expansion Strategy: We intend to continue targeting the approximately 5,500 remaining prospective accounts through the efforts of our growing and increasingly tenured team of territory managers.
New Market Indication for Delirium: We expect to submit an application to FDA later this year for a novel algorithm for detection and monitoring of delirium.
Gross Margin Q4 2024: Gross margin for the fourth quarter of 2024 was 88% compared to 85% in the prior year period.
Operating Expenses Q4 2024: Total operating expenses for the fourth quarter of 2024 were $29.1 million, an increase of 49% compared to $19.5 million in the fourth quarter of 2023.
Commercial Organization Expansion: We are currently on track to our goal of expanding our account acquisition team to 55 territory managers by mid-2025.
Investment in R&D: We expect to accelerate hiring plans for key R&D talent and make greater investments across our pipeline to facilitate TAM expansion.
Regulatory Issues: CeriBell is preparing to submit a 510(k) application with the FDA for expanding the Clarity indication to include pediatric patients, which involves regulatory risks and uncertainties.
Supply Chain Challenges: The company faces a 35% tariff on materials sourced from China, which has increased from 25% in 2024, potentially impacting costs and supply chain efficiency.
Competitive Pressures: CeriBell operates in a competitive market with approximately 6,000 acute care facilities in the U.S. that could benefit from their offerings, indicating a need for continuous innovation and market penetration.
Economic Factors: The transition to operating as a public company has increased costs, particularly in stock-based compensation, which is expected to contribute approximately $15 million to operating expenses for the full-year 2025.
Operational Expenses: Total operating expenses increased significantly, reflecting investments in the commercial organization and the costs associated with transitioning to a public company, which could impact profitability.
Commercial Strategy for 2025: Maintain key areas of focus and build upon success in 2024, expanding account acquisition team to 55 territory managers by mid-2025.
R&D Pipeline Expansion: Invest in optimizing algorithm performance and user experience, with plans to expand indications beyond seizure management.
New Product Indications: Expect to submit a 510(k) application for pediatric patients in late 2024 and a separate application for neonate Clarity algorithm in 2026.
Delirium Detection Algorithm: Preparing to submit an application to the FDA later this year for a new algorithm targeting delirium management.
Long-term Growth Opportunities: Develop solutions for neurological and psychiatric conditions beyond acute care, leveraging existing technology and expertise.
2025 Revenue Guidance: Expect total revenue in the range of $81 million to $85 million, representing 24% to 30% growth over 2024.
Gross Margin Expectations: Expect gross margins to normalize to mid to high 80% range, accounting for increased tariffs.
Operating Expenses: Expect stock-based compensation to contribute approximately $15 million to operating expenses for 2025.
Cash Flow Breakeven Goal: Remain committed to achieving cash flow breakeven with confidence from cash on hand.
Net Loss for Q4 2024: $12.6 million
Net Loss for Full-Year 2024: $40.5 million
Cash and Cash Equivalents as of December 31, 2024: $194.4 million
Proceeds from IPO: Approximately $188 million
Expected Total Revenue for 2025: $81 million to $85 million
Stock-Based Compensation for Full-Year 2025: Approximately $15 million
Ceribell's earnings call presents a positive outlook with raised revenue guidance, strong gross margins, and strategic supply chain adjustments. Their market expansion into pediatrics and neonates, coupled with a new 510(k) clearance, enhances growth prospects. While competition and IP litigation pose risks, they haven't significantly impacted performance. The Q&A section reveals optimism about account growth and strategic partnerships, with some concerns about resource limitations and competition. Overall, the company's strategic initiatives and optimistic guidance suggest a positive stock price movement over the next two weeks.
The earnings call summary indicates positive developments such as improved gross margins due to supply chain diversification, effective cost management, and promising product launches. The Q&A reveals management's strategic focus on market expansion and addressing challenges, although some responses lack specificity. Overall, the company's initiatives and optimistic outlook, despite some uncertainties, suggest a positive sentiment. This, combined with the potential for margin improvements and market expansion, points to a likely positive stock price movement over the next two weeks.
The company reported significant revenue growth and improved gross margins, indicating strong financial performance. Despite increased operating expenses leading to a net loss, the guidance remains optimistic with continued investments in growth. The Q&A revealed some uncertainties about future guidance and FDA submissions, but the overall market strategy and expansion plans are positive. The stock price is likely to react positively over the next two weeks, especially given the record revenue growth and optimistic outlook for 2025.
The earnings report shows strong revenue growth and improved gross margins, suggesting positive financial performance. Despite increased operating expenses and net losses, the company maintains a solid cash position post-IPO. The Q&A indicates strategic investments in sales infrastructure and R&D, with a focus on future growth. While there are concerns about supply chain tariffs and unclear FDA submission details, the overall sentiment is optimistic, with expectations of accelerated growth post-2025. Given these factors, the stock is likely to experience a positive movement in the near term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
